You just read:

Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes

News provided by

MEI Pharma, Inc.

May 13, 2020, 17:05 ET